Get the Stockscreener App
8.33
5.23%
-0.46
After Hours:
7.87
-0.46
-5.52%
Xencor Inc stock is traded at $8.33, with a volume of 935.73K.
It is down -5.23% in the last 24 hours and down -5.45% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$8.79
Open:
$8.84
24h Volume:
935.73K
Relative Volume:
1.16
Market Cap:
$801.17M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-2.8824
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
-26.02%
1M Performance:
-5.45%
6M Performance:
-64.73%
1Y Performance:
-64.61%
1-Day Range:
$8.31
$9.37
1-Week Range:
$7.85
$11.14
52-Week Range:
$7.16
$27.24
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
8.33 | 801.17M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Barclays Issues Pessimistic Forecast for Xencor (NASDAQ:XNCR) Stock Price - Defense World
JPMorgan cuts Xencor stock price target to $20, keeps overweight rating - Investing.com Australia
Xencor Inc earnings missed by $0.04, revenue topped estimates - Investing.com Nigeria
Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Bar - GuruFocus
Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Barclays | XNCR Stock News - GuruFocus
JPMorgan cuts Xencor stock price target to $20, keeps overweight rating By Investing.com - Investing.com South Africa
Xencor Reports First Quarter 2025 Financial Results - BioSpace
Xencor: Q1 Earnings Snapshot - MySA
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
(XNCR) Technical Data - news.stocktradersdaily.com
Xencor (NASDAQ:XNCR) Earns Outperform Rating from Wedbush - Defense World
Healthy Upside Potential: Xencor Inc (XNCR) - Sete News
Xencor reports positive trial results for inflammatory bowel disease treatment - MSN
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Wells Fargo & Company MN Raises Stock Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Analyzing Xencor Inc (XNCR) After Recent Trading Activity - knoxdaily.com
Trading Day Triumph: Xencor Inc (XNCR) Ends at 10.58, a -0.19 Surge/Plunge - DWinneX
Is Xencor Inc (XNCR) a good investment opportunity? - uspostnews.com
Xencor Announces Promising Phase 1 Study Results - TipRanks
Raymond James Financial Inc. Invests $2.33 Million in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor (XNCR) Reports Promising Results and Advances XmAb942 Stu - GuruFocus
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease - BioSpace
Xencor posts trial data for bowel disease drug (XNCR:NASDAQ) - Seeking Alpha
Xencor advances ulcerative colitis treatment into Phase 2b study - Investing.com
Xencor (XNCR) Reports Promising Results and Advances XmAb942 Study | XNCR Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Is Xencor (NASDAQ:XNCR) A Risky Investment? - simplywall.st
LPL Financial LLC Has $452,000 Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Gaining Ground: Xencor Inc (XNCR) Closes Higher at 10.87, Up 2.07 - DWinneX
It is Poised to be a Bull Market for Xencor Inc (XNCR) - Sete News
Equities Analysts Issue Forecasts for Xencor Q1 Earnings - Defense World
Is the Xencor Inc (NASDAQ:XNCR) stock an investment opportunity? - uspostnews.com
Invesco Ltd. Sells 156,130 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
JPMorgan Chase & Co. Sells 9,291 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor Inc Shares Are Up -44.42% Since The Beginning Of The Year - Marketing Sentinel
Xencor Inc (XNCR) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Xencor (NASDAQ:XNCR) Now Covered by Analysts at William Blair - Defense World
William Blair Initiates Coverage of Xencor (XNCR) with Outperform Recommendation - Nasdaq
William Blair starts Xencor stock with Outperform rating By Investing.com - Investing.com Canada
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results - ADVFN
Xencor (XNCR) Receives Outperform Rating from William Blair | XN - GuruFocus
William Blair starts Xencor stock with Outperform rating - Investing.com
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Buy” by Analysts - Defense World
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Alliancebernstein L.P. - Defense World
Geode Capital Management LLC Acquires 179,526 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Geode Capital Management LLC Raises Position in Xencor, Inc. (NASDAQ:XNCR) - The AM Reporter
Wellington Management Group LLP Purchases Shares of 27,491 Xencor, Inc. (NASDAQ:XNCR) - The AM Reporter
27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP - Defense World
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):